Clinical reasoning: An encephalopathic 3-day-old infant

A. A. Gelfand; A. Sznewajs; H. C. Glass; A. C. Jelin; E. H. Sherr

doi:10.1212/WNL.0b013e3182231407

Clinical reasoning: An encephalopathic 3-day-old infant

A. A. Gelfand, A. Sznewajs, H. C. Glass, A. C. Jelin, E. H. Sherr

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	e1-e5
Journal	Neurology
Volume	77
Issue number	1
DOIs	https://doi.org/10.1212/WNL.0b013e3182231407
State	Published - Jul 5 2011
Externally published	Yes

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.0b013e3182231407

Cite this

@article{32281ced5a1e4e569fe30ad3da32b7b4,

title = "Clinical reasoning: An encephalopathic 3-day-old infant",

author = "Gelfand, {A. A.} and A. Sznewajs and Glass, {H. C.} and Jelin, {A. C.} and Sherr, {E. H.}",

note = "Funding Information: Dr. Gelfand is a member of the editorial team for the Resident & Fellow section of Neurology {\textregistered}. A. Sznewajs reports no disclosures. Dr. Glass serves on the editorial board of the Canadian Journal of Neurological Sciences and receives research support from the NIH (NINDS, NCRR) and the March of Dimes. Dr. Jelin reports no disclosures. Dr. Sherr receives research support from Pfizer Inc, the NIH/NINDS, the March of Dimes, Aicardi Syndrome Foundation, Weston Havens Foundation, and the Simons Foundation; holds stock/stock options in Sensorin, Inc., Daiichi Sankyo (Plexxicon, Inc.), Ingenuity Systems, Inc. (his spouse is employed there), and ChemoCentryx, Inc.; and has participated in medico-legal cases. ",

year = "2011",

month = jul,

day = "5",

doi = "10.1212/WNL.0b013e3182231407",

language = "English (US)",

volume = "77",

pages = "e1--e5",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Clinical reasoning

T2 - An encephalopathic 3-day-old infant

AU - Gelfand, A. A.

AU - Sznewajs, A.

AU - Glass, H. C.

AU - Jelin, A. C.

AU - Sherr, E. H.

N1 - Funding Information: Dr. Gelfand is a member of the editorial team for the Resident & Fellow section of Neurology ®. A. Sznewajs reports no disclosures. Dr. Glass serves on the editorial board of the Canadian Journal of Neurological Sciences and receives research support from the NIH (NINDS, NCRR) and the March of Dimes. Dr. Jelin reports no disclosures. Dr. Sherr receives research support from Pfizer Inc, the NIH/NINDS, the March of Dimes, Aicardi Syndrome Foundation, Weston Havens Foundation, and the Simons Foundation; holds stock/stock options in Sensorin, Inc., Daiichi Sankyo (Plexxicon, Inc.), Ingenuity Systems, Inc. (his spouse is employed there), and ChemoCentryx, Inc.; and has participated in medico-legal cases.

PY - 2011/7/5

Y1 - 2011/7/5

UR - http://www.scopus.com/inward/record.url?scp=80051500241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051500241&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e3182231407

DO - 10.1212/WNL.0b013e3182231407

M3 - Article

C2 - 21727263

AN - SCOPUS:80051500241

SN - 0028-3878

VL - 77

SP - e1-e5

JO - Neurology

JF - Neurology

IS - 1

ER -

Clinical reasoning: An encephalopathic 3-day-old infant

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this